Skip to content

Migrainerelief through injections: Understanding the mechanism and additional details

Migraine treatment via injections: Mechanisms and additional information

Migraine Injections: behind the science and additional insights
Migraine Injections: behind the science and additional insights

Migrainerelief through injections: Understanding the mechanism and additional details

New Frontier in Migraine Treatment: CGRP-Specific Injectables

Calcitonin gene-related peptide (CGRP) plays a significant role in the development and progression of migraines. During migraine attacks, CGRP levels increase in blood plasma and saliva, causing blood vessels to dilate, particularly in the brain meninges, and facilitating pain transmission [1][2].

In response to this discovery, a new frontier of migraine-specific therapy options has emerged: injectable treatments that target CGRP. These therapies interfere with CGRP signaling pathways, offering a more targeted approach with reduced side effects compared to traditional treatments [1][3][4].

Preventive Treatments

Four CGRP-specific preventive medications are currently available: eptinezumab, erenumab, fremanezumab, and galcanezumab. While people can self-administer erenumab, fremanezumab, and galcanezumab at home, eptinezumab requires an infusion at an infusion center [4].

Eptinezumab (Vyepti) is the first FDA-approved intravenous anti-CGRP monoclonal antibody for migraine prevention. It is administered every 3 months and has shown rapid bioavailability and significant reduction in monthly migraine days [4].

Galcanezumab and other CGRP ligand or receptor-blocking antibodies work by blocking the CGRP pathway, a key component in migraine pathophysiology [3].

Acute Treatments

For those experiencing acute migraine episodes, two injectable medications have been approved: sumatriptan and dihydroergotamine. These treatments help reduce pain by causing blood vessels to tighten [4].

Cost and Safety Considerations

CGRP-specific drugs can be expensive, with costs around $7,000 per year without insurance coverage [4]. Additionally, there are potential side effects associated with these treatments, including injection site reactions, constipation (with erenumab), hypersensitivity, hypertension (with erenumab), nasopharyngitis (with eptinezumab), and potential unanswered safety questions for those with vascular conditions [4].

It's important to note that pregnant or breastfeeding individuals cannot receive CGRP-specific injectable treatments [4].

Migraine Prevalence

Migraine affects approximately 12% of the population in the United States and 50% globally [4]. While Botox, though not migraine-specific, may be a more effective and affordable option for preventing chronic migraine [4].

In conclusion, CGRP-specific injectables represent a significant advancement in migraine treatment, offering targeted and effective prevention and acute treatment options. However, it's crucial to consider the cost and potential side effects when deciding on the best treatment approach.

  1. Science in the medical-health field has led to the understanding that predictive CGRP plays a pivotal role in the onset and progression of neurological disorders such as migraines.
  2. During a migraine attack, ulcerative levels of CGRP in blood plasma and saliva cause dilation of blood vessels, particularly in the brain meninges, thereby facilitating pain transmission.
  3. In response to this discovery, health-and-wellness seekers now have a new treatment option: CGRP-specific injectables that target and interfere with CGRP signaling pathways.
  4. Four preventive CGRP-specific medications are currently available: eptinezumab, erenumab, fremanezumab, and galcanezumab, with erenumab, fremanezumab, and galcanezumab being self-administered at home, while eptinezumab requires an infusion at an infusion center.
  5. Eptinezumab (Vyepti), the first FDA-approved intravenous anti-CGRP monoclonal antibody for migraine prevention, is administered every 3 months and has demonstrated rapid bioavailability and a significant reduction in monthly migraine days.
  6. Galcanezumab and other CGRP ligand or receptor-blocking antibodies work by blocking the CGRP pathway, a key component in migraine pathophysiology.
  7. For those experiencing acute migraine episodes, migraine-specific treatments such as sumatriptan and dihydroergotamine, which help reduce pain by causing blood vessels to tighten, have been approved.
  8. CGRP-specific drugs can be expensive, with costs around $7,000 per year without insurance coverage, and potential side effects associated with these treatments, including injection site reactions, constipation, hypersensitivity, hypertension, nasopharyngitis, and potential unanswered safety questions for those with vascular conditions.
  9. Pregnant or breastfeeding individuals cannot receive CGRP-specific injectable treatments.
  10. Migraine affects approximately 12% of the population in the United States and 50% globally, making it a prevalent medical-condition.
  11. Despite the effectiveness of CGRP-specific injectables, Botox, though not migraine-specific, may be a more effective and affordable option for preventing chronic migraine.
  12. In conclusion, the advancement of CGRP-specific injectables in the treatment of migraine offers targeted and effective prevention and acute treatment options, but it's essential to consider the cost and potential side effects when deciding on the best treatment approach.

Read also:

    Latest